218 related articles for article (PubMed ID: 12052252)
1. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
Blackburn AC; Jerry DJ
Breast Cancer Res; 2002; 4(3):101-11. PubMed ID: 12052252
[TBL] [Abstract][Full Text] [Related]
2. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
3. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.
Wijnhoven SW; Zwart E; Speksnijder EN; Beems RB; Olive KP; Tuveson DA; Jonkers J; Schaap MM; van den Berg J; Jacks T; van Steeg H; de Vries A
Cancer Res; 2005 Sep; 65(18):8166-73. PubMed ID: 16166291
[TBL] [Abstract][Full Text] [Related]
4. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.
Francis JC; Melchor L; Campbell J; Kendrick H; Wei W; Armisen-Garrido J; Assiotis I; Chen L; Kozarewa I; Fenwick K; Swain A; Smalley MJ; Lord CJ; Ashworth A
J Pathol; 2015 Jun; 236(2):186-200. PubMed ID: 25692405
[TBL] [Abstract][Full Text] [Related]
6. Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome.
Majhi PD; Griner NB; Mayfield JA; Compton S; Kane JJ; Baptiste TA; Dunphy KA; Roberts AL; Schneider SS; Savage EM; Patel D; Blackburn AC; Maurus KJ; Wiesmüller L; Jerry DJ
Oncogene; 2021 Aug; 40(31):5026-5037. PubMed ID: 34183771
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.
Dunphy KA; Blackburn AC; Yan H; O'Connell LR; Jerry DJ
Breast Cancer Res; 2008; 10(3):R43. PubMed ID: 18471300
[TBL] [Abstract][Full Text] [Related]
8. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
Lubet RA; Zhang Z; Wiseman RW; You M
Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
[TBL] [Abstract][Full Text] [Related]
9. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
10. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
[TBL] [Abstract][Full Text] [Related]
11. siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors.
Böhringer M; Obermeier K; Griner N; Waldraff D; Dickinson E; Eirich K; Schindler D; Hagen M; Jerry DJ; Wiesmüller L
Oncogene; 2013 Nov; 32(48):5458-70. PubMed ID: 23435420
[TBL] [Abstract][Full Text] [Related]
12. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
Jonkers J; Meuwissen R; van der Gulden H; Peterse H; van der Valk M; Berns A
Nat Genet; 2001 Dec; 29(4):418-25. PubMed ID: 11694875
[TBL] [Abstract][Full Text] [Related]
13. Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity.
Tao L; Roberts AL; Dunphy KA; Bigelow C; Yan H; Jerry DJ
Stem Cells; 2011 Jan; 29(1):119-27. PubMed ID: 21280161
[TBL] [Abstract][Full Text] [Related]
14. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
15. The p53-deficient mouse: a model for basic and applied cancer studies.
Donehower LA
Semin Cancer Biol; 1996 Oct; 7(5):269-78. PubMed ID: 9110404
[TBL] [Abstract][Full Text] [Related]
16. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
[TBL] [Abstract][Full Text] [Related]
17. [p53 transgenic and knockout mice].
Oda H
Nihon Rinsho; 2000 Jun; 58(6):1250-4. PubMed ID: 10879049
[TBL] [Abstract][Full Text] [Related]
18. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
19. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
[TBL] [Abstract][Full Text] [Related]
20. Environmental carcinogens and p53 tumor-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis.
Medina D; Ullrich R; Meyn R; Wiseman R; Donehower L
Environ Mol Mutagen; 2002; 39(2-3):178-83. PubMed ID: 11921187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
